Search

Influenza A virus A/Darwin/9/2021 SAN-010 (H3N2) antigen (formaldehyde inactivated)

Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (propiolactone inactivated)

Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

DLO6001

DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.

Pentafluoropropane

Pentafluoropropane is under investigation in clinical trial NCT01673061 (Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage).

Hyaluronic acid (non-animal stabilized)

Hyaluronic acid (non-animal stabilized) is under investigation in clinical trial NCT03460158 (Prospective Evaluation of Facial Cosmetic Procedures).

LCP-AtorFen

LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect … LCP-AtorFen is designed to be a once daily tablet offering a powerful and safe treatment of high cholesterol levels, addressing three primary cardiovascular risk factors: low density lipoprotein cholesterol

Interleukin-7

Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.

Imidapril

Imidapril has been investigated for the treatment of Kidney, Polycystic, Autosomal Dominant.

Oleic monoethanolamide

Amineptine

The Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until